IV
IVX.AU Invion Ltd
- Market cap
- AUD 3.76M
- P/E
- -
- P/B
- 0.71x
- ROE
- -105.9%
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is IVX.AU undervalued?
Graham numberThe Graham number of Invion Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Invion Ltd fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-105.9%), below 10%.
ROA 0/1
Return on assets (-69.0%) is below the industry median (-8.9%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (48.8%) is above the industry median (42.8%).
Revenue Growth 0/2
Revenue shrank 54.6% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (29.1%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.2 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.7x) is below the industry median (2.0x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Invion Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Invion Ltd
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in South Korea. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme (GBM), lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial…
Full company profileInvion Ltd financial statements
Invion Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 738K | 3.88M | 3.48M | 2.33M | 3.29M | 4.10M | 3.69M | 0.00 | 385K |
| Gross Profit | -1.24M | 367K | 1.63M | 1.92M | 811K | 969K | 1.21M | 1.00M | -1.29M | 385K |
| Operating Income | -2.09M | -960K | -2.52M | -1.03M | -1.57M | -2.32M | -1.65M | -5.68M | -5.29M | -3.94M |
| EBITDA | -840K | -1.76M | -2.21M | -749K | -1.29M | -1.82M | -965K | -4.57M | -4.00M | -3.94M |
| Net Income | -2.20M | -927K | -2.55M | -954K | -1.48M | -2.24M | -1.61M | -5.63M | -8.81M | -5.63M |
| EPS | -0.14 | -0.02 | 0.00 | 0.00 | 0.00 | -0.04 | -0.03 | -0.09 | -0.12 | -0.06 |
| Balance Sheet | ||||||||||
| Total Assets | 5.81M | 10.3M | 6.06M | 5.76M | 5.64M | 20.0M | 19.0M | 15.5M | 9.49M | 8.17M |
| Total Liabilities | 1.80M | 2.44M | 605K | 327K | 851K | 462K | 651K | 1.01M | 1.24M | 2.85M |
| Shareholders' Equity | 4.01M | 7.91M | 5.46M | 5.43M | 4.79M | 19.6M | 18.4M | 14.4M | 8.25M | 5.32M |
| Cash & Short-term Investments | 917K | 2.89M | 771K | 619K | 1.04M | 8.47M | 4.08M | 784K | 850K | 592K |
| Total Debt | 3.74M | 20.3K | - | - | - | - | - | - | - | 1.55M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -247K | 707K | -2.11M | -152K | 418K | -1.11M | -1.81M | -2.40M | -2.97M | -2.37M |
| Capital Expenditure | 6.05K | 6.05K | 6.05K | 75.8K | 7.25M | 7.25M | 2.58M | 900K | 0.00 | 4.11K |
| Free Cash Flow | -247K | 707K | -2.11M | -152K | 418K | -8.36M | -4.39M | -3.30M | -2.97M | -2.38M |
| Ratios | ||||||||||
| ROE | -54.9% | -11.7% | -46.7% | -17.6% | -31.0% | -11.4% | -8.8% | -39.0% | -106.8% | -105.9% |
| ROA | -37.8% | -9.0% | -42.0% | -16.6% | -26.3% | -11.2% | -8.5% | -36.4% | -92.8% | -69.0% |
| Net Profit Margin | - | -125.6% | -65.6% | -27.4% | -63.6% | -68.1% | -39.3% | -152.3% | - | -1,461.9% |
| Debt to Equity | 0.93x | 0.00x | - | - | - | - | - | - | - | 0.29x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Invion Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | AUD 982K | 0.03 | - |
| 2017 | AUD 663K | 0.04 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:100 on Nov 20, 2024.
Who owns Invion Ltd
- Insiders 41.75%
- Institutions 0.00%
- Public & others 58.25%
- Shares outstanding 111M
- Free float 59.3M
Invion Ltd company profile
- Company name
- Invion Ltd
- Ticker
- IVX.AU
- ISIN
- AU000000IVX4
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- June
- Address
- 385 Bourke Street, Melbourne, VIC, Australia, 3000
- Phone
- 61 3 9692 7222
- Website
- inviongroup.com
About Invion Ltd
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in South Korea. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme (GBM), lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer. The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr. I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Invion Ltd management
3- Mr. Thian ChewExecutive Chairman & CEO
- Ms. Melanie Jaye Leydin B.Bus, C.A.CFO, Company Secretary & Non-Executive Director · born 1973
- Dr. Dean NaylorHead of Intellectual Property Development